Juvaris BioTherapeutics Completes Second Close on $25M Series B Financing

Juvaris BioTherapeutics, Inc., a Burlingame, CA-based biotechnology company developing adjuvanted vaccines for infectious diseases, has completed a second close on its Series B equity financing of up to $25m.
The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.
The funds will be used to advance Juvaris’ novel adjuvant platform of cationic-lipid DNA complexes, which are designed to significantly improve the quality and quantity of immune responses achievable with vaccines, along with the company’s proprietary adjuvanted vaccine pipeline.

Join the discussion